Last reviewed · How we verify

NCT01064063: Vanguard

Randomized Controlled Clinical Evaluation to Compare Vanguard Cruciate Retaining and AGC Total Condylar Knee Implants

Completed NA Last updated 26 November 2025
What this trial tests

NA trial testing Vanguard CR in Osteoarthritis in 150 participants. Completed in 10 May 2022.

Timeline
15 February 2011
Primary endpoint
15 December 2013
10 May 2022

Quick facts

Lead sponsorZimmer Biomet
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment150
Start date15 February 2011
Primary completion15 December 2013
Estimated completion10 May 2022
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Zimmer Biomet — full company profile →

Who can join

18 and older, any sex, with Osteoarthritis or Rheumatoid Arthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This evaluation is being conducted on the relative new knee system, the Vanguard Cruciate Retaining (CR) to evaluate clinical efficacy of the Vanguard CR components.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Osteoarthritis

Currently open trials in the same condition.

Other Zimmer Biomet trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01064063.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing